Orum Therapeutics Inc is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is principally engaged in the research and development of new biopharmaceuticals for cancer and immune diseases based on its platforms.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-16	₩45,400.00	-6.20%	61,250
26-07-15	₩48,400.00	+7.80%	84,931
26-07-14	₩44,900.00	-1.10%	117,774
26-07-13	₩45,400.00	-6.78%	106,537
26-07-10	₩48,700.00	+5.18%	94,099

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2026-07-16			5-day change	1st Jan Change
45,400.00 ^KRW	-6.20%		-1.94%	-62.17%

07-15	Alert wrongly tagged to Orum Therapeutics withdrawn	RE
04-17	Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate	CI

Market Cap	986B 663M 580M 535M 493M 929M 63.86B 950M 6.39B 2.51B 31.28B 2.49B 2.44B 108B	P/E 2024 *	-	P/E 2025	-59.5x
Enterprise Value	879B 591M 517M 477M 439M 828M 56.92B 847M 5.7B 2.24B 27.88B 2.22B 2.17B 95.97B	EV / Sales 2024 *	-	EV / Sales 2025	103,580x
Free-Float	84.16%	Yield 2024 *	-	Yield 2025	-

07-15	Alert wrongly tagged to Orum Therapeutics withdrawn	RE
04-17	Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate	CI
04-13	Orum Therapeutics, Inc. Appoints Maria Koehler and Geoff Meyerson to Board of Directors	CI
01-15	Orum Therapeutics, Inc. announced that it has received KRW 24.999873175 billion in funding from a group of investors	CI
01-04	Orum Therapeutics Appoints Chad May as Chief Scientific Officer	CI
12-18	Orum Therapeutics, Inc. announced that it expects to receive KRW 24.999873175 billion in funding from a group of investors	CI
11-03	Orum Therapeutics Announces Presentation of Preclinical Data for Orm-1153 At the 2025 American Society of Hematology Annual Meeting	CI
25-10-15	Orum Therapeutics Appoints Dorin Toader as Head of Platform Technology	CI
25-06-22	Orum Therapeutics, Inc.(KOSDAQ:A475830) added to S&P Global BMI Index	CI
25-02-07	Orum Therapeutics, Inc. has completed an IPO in the amount of KRW 50 billion.	CI
24-07-16	Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex Pharmaceuticals for the Use of Orum's TPD2 Technology to Develop Novel Degrader-Antibody Conjugates	CI

12-19	Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases	AQ
25-10-15	Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orums Degrader-Antibody Conjugate Payload Platforms and Expand TPD Therapeutic Applications	AQ

Orum Therapeutics, Inc. Stock

Stocks

A475830

KR7475830006

Biotechnology & Medical Research

Valuation: Orum Therapeutics, Inc.

Chart: Orum Therapeutics, Inc.

Latest news : Orum Therapeutics, Inc.

Press Releases: Orum Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Orum Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-6.20%
1 week	-1.94%
Current month	-23.31%
1 month	-28.73%
3 months	-48.35%
6 months	-62.73%
Current year	-62.17%

1 week	43,000	50,400
1 month	43,000	69,300
Current year	43,000	146,600
1 year	20,500	146,600
3 years	15,950	146,600
5 years	15,950	146,600
10 years	15,950	146,600

Manager	Title	Age	Since
Seung-Ju Lee CEO	Chief Executive Officer	52	2016-08-16
In-Tae Jeong DFI	Director of Finance/CFO	44	2023-10-22
Chad May CTO	Chief Tech/Sci/R&D Officer	-	2026-01-04

Director	Title	Age	Since
Seung-Ju Lee BRD	Director/Board Member	52	2016-08-16
In-Tae Jeong BRD	Director/Board Member	44	2023-10-22
Un-Nam Park BRD	Director/Board Member	55	2019-03-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/21/25	In-Tae Jeong	Free	Chief Financial Officer	10,000	-
2/21/25	Un-Nam Park	Free	Director	60,000	-
2/21/25	Seung-Ju Lee	Free	Founder	3,388,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORUM THERAPEUTICS, INC.	-6.20%	-1.94%	+113.65%	-	666M
WUXI APPTEC CO., LTD.	-7.17%	-2.63%	+49.59%	+74.24%	55.98B
ARGENX SE	+0.24%	-1.54%	+53.22%	+71.85%	53.69B
INSMED INCORPORATED	+0.80%	-6.31%	+3.98%	+423.29%	23.29B
BIONTECH SE	-0.09%	-0.01%	-17.62%	-14.67%	23.15B
WUXI BIOLOGICS (CAYMAN) INC.	-5.95%	-0.22%	+35.96%	-9.58%	20.58B
GENMAB A/S	-1.14%	-3.16%	+32.88%	-28.80%	17.76B
PHARMAESSENTIA CORPORATION	-5.16%	-7.00%	+177.56%	+326.39%	16.09B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.91%	+2.40%	+36.86%	+636.97%	15.93B
EXELIXIS, INC.	+0.43%	-1.03%	+24.63%	+191.40%	14B
Average	-3.12%	-1.81%	+51.07%	+185.68%	24.12B
Weighted average by Cap.	-2.93%	-2.21%	+43.57%	+145.14%

	2024	2025
Net sales	20.91B 14.06M 12.29M 11.34M 10.45M 19.7M 1.35B 20.13M 136M 53.3M 663M 52.8M 51.64M 2.28B	23.56M 15.85K 13.85K 12.78K 11.78K 22.2K 1.53M 22.69K 153K 60.08K 747K 59.51K 58.21K 2.57M
Net income	-5.74B -3.86M -3.37M -3.11M -2.87M -5.41M -372M -5.53M -37.21M -14.63M -182M -14.5M -14.18M -627M	-41.97B -28.22M -24.67M -22.76M -20.98M -39.54M -2.72B -40.42M -272M -107M -1.33B -106M -104M -4.58B
Net Debt	-90.47B -60.84M -53.17M -49.06M -45.22M -85.24M -5.86B -87.13M -586M -231M -2.87B -228M -223M -9.88B	-107B -72.03M -62.94M -58.08M -53.54M -101M -6.94B -103M -694M -273M -3.4B -270M -265M -11.69B